SIMPLE NONRADIOACTIVE DETECTION OF THE CFTR MUTATION N1303K BY ARTIFICIAL CREATION OF A RESTRICTION SITE

被引：4

作者：

BAL, J

RININSLAND, F

OSBORNE, L

REISS, J

机构：

[1] UNIV GOTTINGEN,INST HUMAN GENET,GOSSLERSTR 12D,W-3400 GOTTINGEN,GERMANY

[2] NATL HEART & LUNG INST,DEPT CYST FIBROSIS,LONDON SW3 6LR,ENGLAND

来源：

MOLECULAR AND CELLULAR PROBES | 1992年 / 6卷 / 01期

关键词：

ARTIFICIAL RESTRICTION SITE; CYSTIC FIBROSIS; MUTATION DETECTION; N1303K; POLYMERASE CHAIN REACTION;

D O I：

10.1016/0890-8508(92)90065-6

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

N1303K is one of the most frequent non-ΔF508 mutations causing cystic fibrosis in Central Europe. Since no restriction site is altered by this mutation and no other frequent mutations are known so far in exon 21, the detection requires a separate and laborious test. A mismatched primer was used to create an artificial Hin dlll site in amplified wildtype DNA, which is destroyed by the mutation. This allows for rapid and convenient detection by restriction enzyme digestion. © 1992.

引用

页码：9 / 11

页数：3

共 30 条

[1] EFFECTS OF N1303K MUTATION ON CFTR GATING
DeStefano, S.
Hwang, T.
PEDIATRIC PULMONOLOGY, 2017, 52 : S218 - S218
[2] CFTR Modulator Therapy For N1303K Mutations
Barletta, P.
Ortiz, M. G. Tupayachi
Baumlin, N.
Salathe, M. A.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
[3] INCIDENCE AND EXPRESSION OF THE N1303K MUTATION OF THE CYSTIC-FIBROSIS (CFTR) GENE
OSBORNE, L
SANTIS, G
SCHWARZ, M
KLINGER, K
DORK, T
MCINTOSH, I
SCHWARTZ, M
NUNES, V
MACEK, M
REISS, J
HIGHSMITH, WE
MCMAHON, R
NOVELLI, G
MALIK, N
BURGER, J
ANVRET, M
WALLACE, A
WILLIAMS, C
MATHEW, C
ROZEN, R
GRAHAM, C
GASPARINI, P
BAL, J
CASSIMAN, JJ
BALASSOPOULOU, A
DAVIDOW, L
RASKIN, S
KALAYDJIEVA, L
KEREM, B
RICHARDS, S
SIMONBOUY, B
SUPER, M
WULBRAND, U
KESTON, M
ESTIVILL, X
VAVROVA, V
FRIEDMAN, KJ
BARTON, D
DALLAPICCOLA, B
STUHRMANN, M
BEARDS, F
HILL, AJM
PIGNATTI, PF
CUPPENS, H
ANGELICHEVA, D
TUMMLER, B
BROCK, DJH
CASALS, T
MACEK, M
SCHMIDTKE, J
HUMAN GENETICS, 1992, 89 (06) : 653 - 658
[4] Physiological and pharmacological characterization of the N1303K mutant CFTR
DeStefano, Samantha
Gees, Maarten
Hwang, Tzyh-Chang
JOURNAL OF CYSTIC FIBROSIS, 2018, 17 (05) : 573 - 581
[5] Bilateral spontaneous pneumothorax in a newborn with N1303K mutation of cystic fibrosis (CFTR) gene
Ataseven, Fevzi
Ozer, Samet
Yilmaz, Resul
Senayli, Atilla
TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX, 2010, 58 (02): : 181 - 183
[6] N1303K mutation and diabetes mellitus in cystic fibrosis
Cotellessa, M
Mazzella, M
Bruno, C
Buzzanca, C
Minicucci, L
Gandino, M
Romano, L
Romano, C
ARCHIVES OF DISEASE IN CHILDHOOD, 1996, 75 (06) : 546 - 546
[7] Comprehensive Assessment of CFTR Modulators' Therapeutic Efficiency for N1303K Variant
Efremova, Anna
Kashirskaya, Nataliya
Krasovskiy, Stanislav
Melyanovskaya, Yuliya
Krasnova, Maria
Mokrousova, Diana
Bulatenko, Nataliya
Kondratyeva, Elena
Makhnach, Oleg
Bukharova, Tatiana
Zinchenko, Rena
Kutsev, Sergey
Goldshtein, Dmitry
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (05)
[8] EVOYON - COMPUTATIONAL DISCOVERY OF AN N1303K MUTATION SPECIFIC DRUG
Inbar, O.
Buch, I
PEDIATRIC PULMONOLOGY, 2017, 52 : S296 - S296
[9] Triple CFTR modulator therapy in a patient with homozygous N1303K mutation, Mycobacterium abscessus infection and liver cirrhosis
Thee, S.
Ziegahn, N.
Graeber, S. Y.
Balazs, A.
Rubil, T.
Mall, M. A.
Stahl, M.
KLINISCHE PADIATRIE, 2022, 234 (05): : 320 - 320
[10] Cystic fibrosis airway inflammation enables elexacaftor/ tezacaftor/ivacaftor-mediated rescue of N1303K CFTR mutation
Gentzsch, Martina
Baker, Brooke
Cholon, Deborah M.
Kam, Charissa W.
McKinzie, Cameron J.
Despotes, Katherine A.
Boyles, Susan E.
Quinney, Nancy L.
Esther, Charles R., Jr.
Ribeiro, Carla M. P.
ERJ OPEN RESEARCH, 2024, 10 (01)

← 1 2 3 →